|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In total, 258 measurements of CD19+ lymphocyte counts were collected from 39 children with 8 autoimmune diseases.
|
31026092 |
2019 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Exaggereative immune system causing higher expression of B cell associated markers (CD19) leading to autoimmune condition in POF.
|
29181820 |
2018 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here in this review, we summarize the latest development on the major functions of CD19 as both positive and negative regulator of BCR signaling in different situations and highlight the correlation and mechanisms of disturbed CD19 expression with autoimmune diseases and B cell lymphomas.
|
28153605 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Although efficacy was related to the level of CD4 T-cell depletion, the observations that CD52 depletion of CD19 B cells was less marked in lymphoid organs than in the blood provides a rationale for the rapid B-cell hyper-repopulation that occurs following alemtuzumab administration in MS. That B cells repopulate in the relative absence of T-cell regulatory mechanisms that promote immune tolerance may account for the secondary B-cell autoimmunities, which occur following alemtuzumab treatment of MS.
|
27925187 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate treatment with MEDI-551, a humanized anti-human CD19 monoclonal antibody, in a model of autoimmunity involving mice transgenic (Tg) for Sle1 and human CD19 (hCD19).
|
26606525 |
2016 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This PC gene expression signature was used for monitoring changes in PC levels following anti-CD19 therapy, for evaluating the relationship between PCs and other autoimmune disease-related genes, and for estimating PC levels in affected blood and tissue from patients with multiple autoimmune diseases.
|
24431284 |
2014 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These novel successful anti-CD19 agents may have the potential to be used in other fields, such as autoimmunity.
|
23885836 |
2014 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The findings of reduced levels of CD19 are implicative for the efficacy of epratuzumab in autoimmune diseases because elevated CD19 has been correlated with susceptibility to SLE in animal models as well as in patients.
|
23821660 |
2013 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Remarkably, CD19 loss or B-cell depletion using antimouse CD20 antibody suppresses the development of skin hyperplasia and autoimmunity in tight-skin mice.
|
21545850 |
2011 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The identification of human CD19-L may lead to therapeutic innovation for B-lineage ALL and other B-lineage lymphoid malignancies as well as B-cell lymphoproliferative states and systemic autoimmunity.
|
21323891 |
2011 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Remarkably, CD19 loss or B-cell depletion using antimouse CD20 antibody suppresses the development of skin hyperplasia and autoimmunity in tight-skin mice.
|
20175836 |
2010 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Because CD19(+)CD5(+) B cells are important producers of IgA and contribute to several autoimmune diseases, they may play an important role in IgA nephropathy.
|
18650480 |
2008 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.
|
16217038 |
2005 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In TSK/+ mice overexpressing CD19, skin thickness did not increase, although anti-topo I Ab levels were significantly augmented, indicating that abnormal CD19 signaling influences autoimmunity in TSK/+ mice and also that anti-topo I Ab does not have a pathogenic role.
|
15277237 |
2004 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that modest changes in the expression or function of regulatory molecules such as CD19 may shift the balance between tolerance and immunity to autoimmunity.
|
11086109 |
2000 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, CD19 overexpression shifts the balance between tolerance and immunity to autoimmunity by augmenting antigen receptor signaling.
|
9382890 |
1997 |